2023年中国脑膜炎疫苗行业概览

Investment Rating - The report indicates a positive investment outlook for the meningitis vaccine industry in China, with a projected market growth from CNY 27.5 billion in 2022 to CNY 36.6 billion by 2027, reflecting a compound annual growth rate (CAGR) of 5.2% [2][27]. Core Insights - The meningitis vaccine market in China has experienced fluctuating growth, with a market size increase from CNY 24.1 billion in 2018 to CNY 27.5 billion in 2022, achieving a CAGR of 3.4% [2][27]. - The decline in birth rates has led to a decrease in the total number of meningitis vaccine approvals, impacting overall market dynamics [3][31]. - The number of companies approved to produce meningitis vaccines has increased, leading to a diversification of vaccine types available in the market [4][34]. Summary by Sections Industry Overview - The primary target group for meningitis vaccination is children aged 3 months to 5 years, requiring 2-3 doses [3][31]. - The approval quantity of meningitis vaccines has decreased from 59.99 million doses in 2017 to 40.86 million doses in 2022, with a CAGR of -7.4% [33]. Market Size - The meningitis vaccine market is projected to grow to CNY 36.6 billion from 2023 to 2027, driven by the increasing number of approved vaccine manufacturers and the shift towards more effective vaccine types [27][25]. - The market is influenced by the declining birth rate, which has reduced the number of eligible children for vaccination [29][31]. Competitive Landscape - The market is highly concentrated, with the top three companies—Zhifei Biological, CanSino Biologics, and Watson Biotech—holding over 70% of the market share [68][64]. - Zhifei Biological and CanSino Biologics are projected to maintain significant market shares of 27.2% and 26.2% respectively in 2023 [68][70]. Vaccine Types and Efficacy - The report highlights the superiority of polysaccharide conjugate vaccines (MPCV) over polysaccharide vaccines (MPV) in terms of immunogenicity and durability [20][22]. - The introduction of new vaccines, such as the ACYW135 polysaccharide conjugate vaccine by CanSino, has rapidly captured market share since its approval in 2021 [35][37]. Future Trends - The report anticipates a shift towards the adoption of MPCV as the primary growth driver in the industry, supported by increasing healthcare spending and public awareness of disease prevention [54][55]. - There is a growing emphasis on developing vaccines targeting the B group meningococcal strains, which are currently not available in the Chinese market [27][64].